Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.60 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.60 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.60 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.60 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.60 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.60 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.60 |
| ▸ | RAD52 | P43351 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL23004428 | 1.00 | HTT (0.63) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| Bromide SCHEMBL9357962 | 1.00 | HTT (0.63) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| Bromide SCHEMBL9693481 | 1.00 | HTT (0.63) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| Bromide SCHEMBL2761290 | 1.00 | HTT (0.63) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| Bromide SCHEMBL23004362 | 1.00 | HTT (0.63) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| SCHEMBL2870209 | 0.98 | HTT (0.66) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| SCHEMBL5293081 | 0.98 | HTT (0.66) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| SCHEMBL2861428 | 0.98 | HTT (0.66) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| SCHEMBL4066900 | 0.98 | HTT (0.66) | HTTHSP90AA1RAD52CHRM2ADRA2A | |
| SCHEMBL5305045 | 0.98 | HTT (0.66) | HTTHSP90AA1RAD52CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9555394-B2 | Method of making ionic liquid mediated sol-gel sorbents | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3027216-A1 | COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY- WATER SOLUBLE DRUGS | MW Encap Limited (GB) | 2016-06-08 | — | — | EP | disclosed |
| US-20160151503-A1 | COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY-WATER SOLUBLE DRUGS | MW ENCAP LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| WO-2015013772-A1 | COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY- WATER SOLUBLE DRUGS | MONASH UNIVERSITY (AU) | 2015-02-05 | — | — | WO | disclosed |
| US-20140057048-A1 | METHOD OF MAKING IONIC LIQUID MEDIATED SOL-GEL SORBENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-27 | — | — | US | disclosed |
| US-8623279-B2 | Ionic liquid mediated sol-gel sorbents | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120128551-A1 | IONIC LIQUID MEDIATED SOL-GEL SORBENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010135660-A2 | IONIC LIQUID MEDIATED SOL-GEL SORBENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-11-25 | — | — | WO | disclosed |
| EP-0468404-B1 | Process for preparing di-tert.-butyl dicarbonate | SUMITOMO CHEMICAL CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5151542-A | Reacting an alkali metal tert-butyl carbonate with methanesulfonyl chloride | SUMITOMO CHEMICAL CO., LTD. (JP) | 1992-09-29 | — | — | US | disclosed |
| EP-0468404-A2 | Process for preparing di-tert.-butyl dicarbonate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151503-A1 | COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY-WATER SOLUBLE DRUGS | ABCG2, SLC7A1, ABCB11 | CHRM2 1952/4885CHRM1 2578/4885ACHE 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.